Alpha Teknova, Inc. (TKNO)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $7.86
- As of
Kresmion compiles this page from TKNO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Alpha Teknova, Inc. (TKNO): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-21.
See the full TKNO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TKNO on one page. Preview it with sample data, then open it live with a free account.
Preview the TKNO dossierActive events for TKNO
- high13F: large reduction
CITADEL ADVISORS LLC cut 62% of TKNO (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 83% of TKNO (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 31.6%, EPS $-0.06 vs $-0.0877 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 31.4% - EPS $-0.07 vs $-0.102 estimate
- mediumEarnings above estimates
Beat consensus by 31.4% - EPS $-0.07 vs $-0.102 estimate
FREE, NO ACCOUNT
Every event on TKNO, as it fires
You are seeing 5 of 7 events recorded on TKNO since 2026-05-31.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TKNO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 02080L102 · 2026Q2 | $426K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 02080L102 · 2026Q2 | $134K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TKNO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TKNO against its peers
TKNO's operating margin of -41.9% ranks in the 19th percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-05-31.
| Metric | TKNO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 40.5M USD | 209M USD | 9 | 16 |
| Gross margin | 33.2% | 50.3% | 19 | 17 |
| Operating margin | -41.9% | -9.1% | 19 | 17 |
| Net margin | -42.6% | -18.7% | 25 | 17 |
| Return on equity | -25.1% | -22.2% | 47 | 15 |
Peers (19): TLRY, VREOF, NIKA, VRNO, KMDA, EOLS, AQST, CGC, ELTP, CRLBF, GLAS, ADCT, AKBA, TSNDF, HROW, DERM, CRDL, CRON, BGM. Left out: BORAY (no annual filing), EVO (period gap), LFCR (no annual filing), ASRT.D (no annual filing), PHBI (period gap), OGI (period gap). Fiscal periods ending between 2025-09-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (TKNO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TKNO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TKNO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.